Overview

Abemaciclib in Patients With Oligodendroglioma

Status:
Recruiting
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma
Phase:
Phase 2
Details
Lead Sponsor:
University of Pennsylvania